Therefore, we aimed to evaluate TROP2 expression levels in metastases of patients with cisplatin-resistant GCTs [MET(-R)] and to assess the cytotoxic effectiveness of SG in GCT cell lines, including cisplatin-resistant subclones. The gene discussed is TACSTD2; the disease is granular cell tumor.